LGI1 and encephalitis: Randomized placebo-controlled trial in LGI1 (leucine-rich glioma-inactivated 1) – positive encephalitis patients reported a major benefit regarding cognition and seizures after taking IVIGs compared to placebo treatment in 6/8 (75%) patients (4).